Chengguo (Chris) Xing, Ph.D.

Chengguo (Chris) Xing

Professor and Frank A. Duckworth Eminent Scholar

Medicinal Chemistry

OFFICE: Medical Science Building P6-04


PHONE: 352-294-8511

CV: Link to CV



  • Ph.D., Arizona State University
  • B.S., Dalian University of Technology

Biographical Sketch

Chengguo (Chris) Xing, Ph.D., is a professor and the Frank A. Duckworth Eminent Scholar Chair in the department of medicinal chemistry at the University of Florida College of Pharmacy. Xing received his B.S. degree from the Dalian University of Technology and obtained his Ph.D. degree from Arizona State University. He completed postdoctoral training at Harvard University. Xing started his independent research career as an assistant professor at the University of Minnesota in 2003, and he was promoted to associate professor in 2009 and professor in 2014. He joined the faculty at the University of Florida in August 2016.


  • UF Cancer Center
  • Society of Toxicology
  • American Association for Cancer Research
  • American Association of the Colleges of Pharmacy
  • American Chemical Society

Research Interests

His team’s research broadly covers the isolation, design and synthesis, and identification of biologically active small molecules, employing such candidates as probes to tackle fundamental health-related biological questions, and evaluating their clinical potentials. Another mission of the research is to educate graduate students, post-doctoral fellows, undergraduate students and other professionals the integration of different disciplines at the interface of chemistry and biology, including pharmacognosy, medicinal chemistry, chemical biology, bioanalytical chemistry and disease/risk biomarkers, molecular, cellular and animal biology. As the Frank A. Duckworth Eminent Scholar at UF, his team’s research will focus on translational development with several indications, including novel therapies selective against multi-drug resistant malignancies, chemopreventive agents against primary carcinogenesis and a natural dietary supplement on neurological disorders with the goal to extend them in the clinical setting. Xing’s work in these areas is currently supported by NIH.

Select Publications

Narayanapillai, S.C.; von Weymarn, L.B.; Carmella, S.G.; Leitzman, L.; Upadhyaya, P.; Hecht, S.S.; Murphy, S.E.; Xing, C.* Dietary Dihydromethysticin (DHM) Increases Glucuronidation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-Butanol (NNAL) in A/J Mice, Potentially Enhancing its Detoxification. Drug Metab. Dispos. 2016, 44(3):422-427.

Narayanapillai1, S.; Balbo, S.; Leitzman, P.; Grill, A.; Upadhyaya, P.; Shaik, A.; Zhou, B.; O’Sullivan, M. G.; Lu, J.; Peterson, L.; Hecht, S. S.*; Xing, C.* Dihydromethysticin (DHM) from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis 2014, 35(10), 2365-2372.

He, W.; Wang, Q.; Srinivasan, B.; Xu, J.; Padilla, M. T.; Wang, X.; Gou, X.; Shen, H.; Xing, C.*; Lin, Y.* A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene 2014, 33(23): 3004-3013.

Das, S. G.#; Hermanson, D. L.#; Bleeker, N.; Lowman, X.; Li, Y.; Kelekar, A.; Xing, C.* Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) a novel scaffold that re-sensitizes multidrug resistant leukemia cells to chemotherapy. ACS Chem. Biol. 2013, 8(2): 327-335.

Srinivasan, B.; Li, Y.; Jing, Y.; Xu, Y.; Xing, C.*; Wang, J. P.* A detection system based on giant magnetoresistive sensors and high-moment magnetic nanoparticles demonstrates zeptomole sensitivity: potential for personalized medicine. Angew. Chem. Int. Ed. 2009, 48 (15):2764-2767.

Srinivasan, B.; Johnson, T. E.; Lad, R.; Xing, C.* Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3′,4′,5′-tetramethyoxychalcone and its analogs as potent NF-кB inhibitors and its anticancer activities. J. Med. Chem. 2009 52(22) 7228-7235.